MedPath

Eravacycline

Generic Name
Eravacycline
Brand Names
Xerava
Drug Type
Small Molecule
Chemical Formula
C27H31FN4O8
CAS Number
1207283-85-9
Unique Ingredient Identifier
07896928ZC
Background

Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .

Indication

Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older .

Associated Conditions
Intraabdominal Infections
Clinical Trials
Related News

FDA Approves Zevtera for S. aureus Bacteremia, Marking First New Treatment in 15 Years

• Basilea Pharmaceutica's Zevtera (ceftobiprole) receives FDA approval for three indications, becoming the first beta-lactam antibiotic approved for Staphylococcus aureus bacteremia. • The approval addresses a significant medical need, with approximately 120,000 S. aureus bloodstream infections occurring annually in the US according to CDC data. • The drug's approval includes coverage for antimicrobial-resistant infections, particularly MRSA, targeting a market projected to reach $5.5 billion by 2030.

Eravacycline Shows Sustained Antimicrobial Activity Against Resistant Bacteria in vitro

• Two in vitro studies presented at IDWeek 2024 demonstrate eravacycline's consistent antimicrobial activity against drug-resistant bacteria. • Eravacycline showed high susceptibility (98.13%) against Carbapenem-resistant _Acinetobacter baumannii_ (CRAB) using ChinaCAST breakpoint of 1 µg/mL. • A global study of 23,127 isolates showed eravacycline maintained high susceptibility against major Gram-positive and Gram-negative bacteria from 2018-2022. • Everest Medicines is committed to further exploring eravacycline's rational use in treating complex infections amid rising antimicrobial resistance.

Everest Medicines Advances mRNA Tumor Vaccine Pipeline Amidst Financial Growth

• Everest Medicines is focusing on mRNA-based therapeutic vaccines, with its first personalized mRNA tumor vaccine, EVM16, now in clinical trials. • Nefecon, Everest's drug for IgA nephropathy, achieved substantial sales of 167 million yuan shortly after launch, highlighting its market potential. • The company's financial performance is strong, with a 158% revenue increase in the first half of the year and expectations to achieve cash break-even by the end of 2025.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy